FDA 483 - Chakrapani Ayurveda Clinic & Research Center - February 18, 2022

An FDA inspection of Chakrapani Ayurveda Clinic & Research Centre in Jaipur, India, revealed numerous deficiencies in their manufacturing and quality control processes for dietary supplements exported to the U.S. The firm failed to establish and follow written procedures for critical operations, including quality control, component and product specifications, and record-keeping. These issues indicate a severe lack of control over product quality, purity, and strength, raising concerns about the safety and compliance of their dietary supplements.